Axitinib

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Renal Cell Carcinoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
EU
  • Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.
Product first approved 2012EMA
JP
  • Treatment of unresectable or metastatic renal cell carcinoma
Product first approved 2012PMDA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (12)
Renal Cell Carcinoma
NCT05738694 · ZHOU FANGJIAN
2023-04-19 – 2027-12-31 · Renal Cell Carcinoma, Neoadjuvant
What this study did
NCT04394975 · Shanghai Junshi Bioscience Co., Ltd.
2020-08-20 – 2024-04-02 · Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1
What this study did
NCT03013946 · AIO-Studien-gGmbH
2017-01-18 – 2024-01-16 · Renal Cell Carcinoma, Metastatic, Renal Cell Cancer, Recurrent
What this study did
Other / comorbidity
NCT06364631 · Gustave Roussy, Cancer Campus, Grand Paris
2024-04-12 – 2032-05-05 · Metastatic Kidney Cancer, Metastatic Kidney Carcinoma
What this study did
NCT05059522 · Pfizer
2021-09-29 – 2026-12-31 · Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer, Solid Tumors
What this study did
NCT00920816 · Pfizer
2009-08-25 – 2021-04-29 · Kidney Neoplasms
What this study did
NCT01599754 · SFJ Pharma Ltd. II
2012-04 – 2018-05 · Clear Cell Renal Carcinoma
What this study did
NCT00471146 · Pfizer
2007-07 – 2010-11 · Carcinoma, Pancreatic Ductal
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT06020352 · Shanghai Pulmonary Hospital, Shanghai, China
2023-08-25 – 2025-07-01 · NSCLC
What this study did
NCT01744249 · Grupo Espanol de Tumores Neuroendocrinos
2011-11 – 2023-12-31 · Neuroendocrine Tumors, Advanced Cancer
What this study did
Phase 2 (106)
Renal Cell Carcinoma
NCT07277972 · Tianjin Medical University Cancer Institute and Hospital
2026-02-15 – 2031-08-31 · RCC, Renal Cell Cancer
What this study did
NCT07744932 · Hebei Medical University Fourth Hospital
2026-08-15 – 2029-12-30 · Oligometastatic Clear Cell Renal Cell Carcinoma
What this study did
NCT05969496 · University of Colorado, Denver
2023-12-04 – 2029-11 · Renal Cancer, Kidney Cancer, Renal Cell Carcinoma, Inferior Vena Cava Thrombosis
What this study did
NCT07469683 · Yonsei University
2026-03 – 2029-10 · Clear Cell Renal Cell Carcinoma, Neoplasms, Malignant Neoplasms, Malignant Neoplasm of Kidney, Except Renal Pelvis
What this study did
NCT07776717 · Fudan University
2026-08-20 – 2028-12-31 · Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
What this study did
NCT07816770 · Fudan University
2026-09-20 – 2028-06-30 · Metastatic Non-Clear Cell Renal Cell Carcinoma, Metastatic Renal Medullary Carcinomas
What this study did
NCT06279403 · RenJi Hospital
2024-03-01 – 2028-06-30 · Immune Checkpoint Inhibitors, Cytoreductive Nephrectomy, Clear Cell Renal Cell Cancer (ccRCC)
What this study did
NCT07123090 · Stephanie Berg
2025-11-24 – 2028-04-01 · Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer, Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Kidney Cancer, Translocation Renal Cell Carcinoma
What this study did
NCT06860386 · H. Lee Moffitt Cancer Center and Research Institute
2025-02-25 – 2028-02 · Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
What this study did
NCT05768464 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2023-02-01 – 2027-12-30 · Non-clear Renal Cell Carcinoma
What this study did
NCT05176288 · Bradley A. McGregor, MD
2024-05-31 – 2027-08-31 · Advanced Clear Cell Renal Cell Carcinoma
What this study did
NCT07172386 · Tianjin Medical University Second Hospital
2025-07-31 – 2027-07-31 · Renal Cell Carcinoma (RCC)
What this study did
NCT07159191 · Peking Union Medical College Hospital
2025-09-01 – 2027-07-20 · Advanced Renal Cell Carcinoma (aRCC)
What this study did
NCT05817903 · Consorzio Oncotech
2023-04-18 – 2027-04-01 · Metastatic Renal Cell Carcinoma
What this study did
NCT03595124 · National Cancer Institute (NCI)
2019-01-08 – 2026-11-13 · Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, TFE3-Rearranged Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma
What this study did
NCT05805501 · Hoffmann-La Roche
2023-04-21 – 2026-10-05 · Renal Cell Carcinoma
What this study did
NCT05096390 · Centre Leon Berard
2022-06-01 – 2026-06 · Papillary Renal Cell Carcinoma Type 2
What this study did
NCT03438708 · University of California, San Diego
2018-03-05 – 2026-03-04 · Clear Cell Renal Cell Carcinoma
What this study did
NCT04387500 · West China Hospital
2021-07-01 – 2026-01-01 · Carcinoma, Renal Cell, Fumarate Hydratase Deficiency, Immunotherapy
What this study did
NCT05256472 · Akeso
2023-07-06 – 2025-12-31 · Renal Cell Carcinoma, First-line Treatment
What this study did
NCT04958473 · Tianjin Medical University Second Hospital
2021-08-01 – 2025-08-01 · Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
What this study did
NCT04370509 · University of California, San Francisco
2021-02-09 – 2025-02-28 · Metastatic Clear Cell Renal Cell Carcinoma, Recurrent Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Clear Cell Renal Cell Carcinoma
What this study did
NCT03341845 · The Netherlands Cancer Institute
2018-03-28 – 2025-01-31 · Renal Cell Carcinoma
What this study did
NCT04698213 · Consorzio Oncotech
2020-10-07 – 2024-10 · Renal Carcinoma Metastatic
What this study did
NCT04995016 · Tianjin Medical University Second Hospital
2021-08-20 – 2023-08-20 · Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
What this study did
NCT01263769 · M.D. Anderson Cancer Center
2011-02 – 2023-06-05 · Kidney Cancer
What this study did
NCT04118855 · RenJi Hospital
2020-03-01 – 2023-03-31 · Neoadjuvant Therapy of Non-metastatic Locally Advanced Renal Cell Carcinoma
What this study did
NCT03592199 · Instituto do Cancer do Estado de São Paulo
2017-12-11 – 2022-12-11 · Clear Cell Renal Cell Carcinoma
What this study did
NCT04385654 · West China Hospital
2020-06 – 2022-06 · Neoadjuvant Therapy, Advanced Cancer, Metastatic Kidney Cancer
What this study did
NCT01693822 · Institute of Cancer Research, United Kingdom
2012-10 – 2022-02-28 · Clear-cell Metastatic Renal Cell Carcinoma
What this study did
NCT03494816 · Scottish Clinical Trials Research Unit
2017-12-15 – 2020-06-10 · Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Non-metastatic Renal Cell Carcinoma
What this study did
NCT02489695 · Centre Leon Berard
2015-10 – 2019-07 · Papillary Renal Cell Carcinoma
What this study did
NCT02700568 · Kidney Cancer Research Bureau
2016-01 – 2018-08 · Carcinoma, Renal Cell, Clear Cell Renal Cell Carcinoma
What this study did
NCT01798446 · Seoul National University Hospital
2013-02 – 2016-12 · Renal Cell Carcinoma, Nonclear Cell, Temsirolimus Resistance
What this study did
NCT01649180 · PrECOG, LLC.
2012-07 – 2016-03 · Renal Cell Carcinoma
What this study did
NCT00076011 · Pfizer
2003-10 – 2007-02 · Kidney Neoplasms
What this study did
Other / comorbidity
NCT04341181 · Ulrik Lassen
2020-08-24 – 2030-04-30 · Cancer, Tumors, Neoplasms, Neoplasia
What this study did
NCT06889649 · Peking University First Hospital
2019-01-01 – 2028-02-20 · Radiation Therapy, Targeted Therapy, Immunotherapy, Renal Cancer Metastatic
What this study did
NCT02925234 · The Netherlands Cancer Institute
2016-08 – 2027-12 · Cancer, Tumors, Neoplasm, Neoplasia
What this study did
NCT06962787 · Sichuan Baili Pharmaceutical Co., Ltd.
2025-07-28 – 2027-12 · Renal Cancer
What this study did
NCT05263609 · University of Oklahoma
2022-06 – 2027-06 · Renal Cell Cancer
What this study did
NCT05384496 · Memorial Sloan Kettering Cancer Center
2022-05-17 – 2027-05 · Mucosal Melanoma
What this study did
NCT04996823 · H. Lee Moffitt Cancer Center and Research Institute
2021-08-04 – 2027-03-29 · Melanoma
What this study did
NCT06211114 · Peking University Cancer Hospital & Institute
2024-02-09 – 2027-02 · Collecting Duct Carcinoma
What this study did
NCT03839498 · Columbia University
2019-01-22 – 2027-02 · Pheochromocytoma, Paraganglioma
What this study did
NCT03297606 · Canadian Cancer Trials Group
2018-03-23 – 2027-01-31 · Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
What this study did
NCT04197219 · Case Comprehensive Cancer Center
2021-02-01 – 2026-12-01 · Recurrent Endometrial Cancer
What this study did
NCT01409200 · M.D. Anderson Cancer Center
2012-03-26 – 2026-02-05 · Metastatic Malignant Neoplasm in Lymph Node, Prostate Ductal Adenocarcinoma, Stage III Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7
What this study did
NCT05420220 · Jiangsu Alphamab Biopharmaceuticals Co., Ltd
2022-07-26 – 2025-12-31 · Advanced Non-small Cell Lung Cancer
What this study did
Phase 1/2 (18)
Renal Cell Carcinoma
NCT07630363 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-05-14 – 2030-04-01 · Advanced Renal Cell Carcinoma (RCC), PTC, Atorvastatin, Targeted Therapy Combined With Immunotherapy
What this study did
NCT07227415 · Pfizer
2026-02-10 – 2028-11-01 · Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm, Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell Metastasis, Advanced or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell, Advanced, Metastatic Renal Cell Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic/Advanced Renal Cell Carcinoma
What this study did
NCT03172754 · Fox Chase Cancer Center
2017-06-12 – 2027-04-06 · Renal Cell Carcinoma
What this study did
NCT05363631 · Fernando Maciel Barbosa
2022-09-19 – 2026-08-25 · Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic
What this study did
NCT05808608 · Hao Zeng
2023-11-17 – 2026-06 · Renal Cell Carcinoma, First-line Treatment, Non Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma
What this study did
NCT04337970 · Memorial Sloan Kettering Cancer Center
2020-04-06 – 2025-05-23 · Kidney Cancer, Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
What this study did
NCT02535533 · Mohammed Milhem
2016-01 – 2025-04-04 · Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
What this study did
NCT02667886 · X4 Pharmaceuticals
2016-04-27 – 2022-04-14 · Clear Cell Renal Cell Carcinoma
What this study did
NCT01806064 · Tracon Pharmaceuticals Inc.
2013-03-08 – 2019-06-12 · Renal Cell Carcinoma
What this study did
Other / comorbidity
NCT06485908 · Assistance Publique Hopitaux De Marseille
2032-02 – 2032-02 · Medulloblastoma, Ependymoma
What this study did
NCT05949632 · Incyte Corporation
2024-04-16 – 2025-06-06 · Advanced Solid Tumors
What this study did
NCT04585815 · Pfizer
2020-11-10 – 2024-10-29 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT03386929 · Worldwide Innovative Network Association
2017-11-29 – 2022-12-29 · Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB
What this study did
NCT03481842 · BioGene Pharmaceutical Ltd.
2021-10-10 – 2021-10-10 · Endometriosis, Endometriosis Ovary, Endometriosis Externa, Endometriosis, Rectum
What this study did
NCT01211275 · The Netherlands Cancer Institute
2009-05-22 – 2013-05-06 · Malignant Pleural Mesothelioma
What this study did
NCT00460603 · Pfizer
2006-01 – 2012-11 · Colorectal Neoplasms
What this study did
NCT00768755 · Pfizer
2009-01 – 2012-03 · Carcinoma, Non-Small Cell Lung
What this study did
NCT00076024 · Pfizer
2004-02 – 2008-11 · Breast Neoplasms
What this study did
Phase 1 (36)
Renal Cell Carcinoma
NCT05536141 · Arcus Biosciences, Inc.
2022-10-26 – 2029-03 · Clear Cell Renal Cell Carcinoma, Solid Tumors
What this study did
NCT04522323 · MedImmune LLC
2020-08-05 – 2025-09-26 · Advanced Renal Cell Carcinoma
What this study did
Other / comorbidity
NCT06424626 · Peking University Cancer Hospital & Institute
2024-05-28 – 2028-12-31 · Melanoma, Mucosal Melanoma, Metastatic Melanoma
What this study did
NCT04693468 · M.D. Anderson Cancer Center
2020-12-01 – 2027-12-31 · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
What this study did
NCT06161558 · National Cancer Institute (NCI)
2025-07-15 – 2025-07-15 · Neoplasms
What this study did
NCT05904730 · Lynkcell Europe
2023-07-11 – 2024-12-26 · Breast Cancer, Ovarian Cancer, Breast Neoplasms, Ovarian Neoplasms, BRCA Mutation, HER2-positive Breast Cancer, HER2-negative Breast Cancer, HER-2 Protein Overexpression
What this study did
NCT04458259 · Pfizer
2020-09-24 – 2024-11-15 · Neoplasm Metastasis
What this study did
NCT04640545 · Nanjing Leads Biolabs Co.,Ltd
2020-05-12 – 2024-08-19 · Advanced Melanoma
What this study did
NCT04873895 · Abramson Cancer Center at Penn Medicine
2022-01-24 – 2024-04-25 · Colorectal Neoplasms Malignant
What this study did
NCT05070221 · Peking University Cancer Hospital & Institute
2021-10-01 – 2023-12-31 · Melanoma Stage IV
What this study did
NCT02493751 · Pfizer
2015-10-26 – 2021-03-04 · Renal Cell Cancer
What this study did
NCT02782403 · M.D. Anderson Cancer Center
2017-03-20 – 2019-11-11 · Accelerated Phase Chronic Myelogenous Leukemia (CML), Blast Phase Chronic Myelogenous Leukemia (CML), Chronic Phase Phase Chronic Myelogenous Leukemia (CML), Philadelphia Chromosome Positive (Ph+) Phase Chronic Myelogenous Leukemia (CML)
What this study did
NCT03289533 · Pfizer
2017-09-08 – 2019-10-25 · Carcinoma, Hepatocellular
What this study did
NCT01999972 · Pfizer
2014-02-26 – 2019-09-05 · Advanced Solid Tumors
What this study did
NCT02814461 · Shin Kong Wu Ho-Su Memorial Hospital
2015-11 – 2018-11 · Advanced Hepatocellular Carcinoma (HCC)
What this study did
NCT03275558 · Center Trials & Treatment
2018-07-17 – 2018-07-17 · Recurrent Glioblastoma, Gliosarcoma, Anaplastic Gliomas
What this study did
NCT02164838 · Children's Oncology Group
2014-09 – 2017-10-19 · Refractory or Recurrent Solid Tumors, Excluding CNS Tumors
What this study did
NCT01334073 · University Hospital, Bordeaux
2011-03 – 2015-01 · Malignant Advanced Solid Tumors, Carcinoma, Renal Cell
What this study did
NCT01540526 · University of Wisconsin, Madison
2012-03 – 2014-12 · Solid Malignancies, Metastatic Castrate-resistant Prostate Cancer
What this study did
NCT00859118 · University of Wisconsin, Madison
2009-02 – 2014-12 · Neoplasms
What this study did
NCT01529138 · Emory University
2011-10 – 2014-03 · Cancer
What this study did
NCT01441388 · Pfizer
2011-12 – 2013-11 · Carcinoma, Renal Cell, Glioblastoma, Carcinoma, Hepatocellular
What this study did
NCT00842244 · Pfizer
2009-04 – 2012-10 · Stomach Neoplasms, Advanced Gastric Cancer
What this study did
NCT00454649 · Pfizer
2005-12 – 2011-04 · Neoplasms
What this study did
NCT00726752 · Pfizer
2008-07 – 2010-04 · Neoplasms
What this study did
NCT01020136 · Pfizer
2010-01 – 2010-02 · Healthy Volunteer
What this study did
NCT00905814 · Pfizer
2009-07 – 2009-09 · Healthy Volunteers
What this study did
NCT00919204 · Pfizer
2009-08 – 2009-08 · Healthy Volunteers
What this study did
NCT00447005 · Pfizer
2007-02 – 2009-08 · Carcinoma
What this study did
NCT00918632 · Pfizer
2009-06 – 2009-07 · Healthy Volunteers
What this study did
NCT00692341 · Pfizer
2008-05 – 2008-10 · Hepatic Insufficiency
What this study did
NCT00949624 · Arog Pharmaceuticals, Inc.
2005-12 – 2008-06 · Advanced Solid Tumors
What this study did
NCT01469052 · Pfizer
2002-11 – 2004-08 · Advanced Solid Tumors
What this study did
Early phase / not applicable (5)
Renal Cell Carcinoma
NCT07500831 · Qilu Hospital of Shandong University
2026-04 – 2029-04 · Carcinoma, Renal Cell, Metastatic Renal Cell Carcinoma, Advanced Renal Cell Carcinoma
What this study did
NCT05816642 · RenJi Hospital
2022-08-01 – 2024-12-31 · Metastatic Renal Cell Carcinoma
What this study did
Other / comorbidity
NCT03826589 · The University of Hong Kong
2019-06-01 – 2024-07-01 · Cervical Cancer
What this study did
NCT00828919 · Pfizer
2003-03-07 – 2023-08-14 · Solid Tumors
What this study did
NCT01486251 · Gustave Roussy, Cancer Campus, Grand Paris
2011-09 – 2014-09 · Colorectal Carcinoma
What this study did
Used as active comparator (4)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2/3 (1)
Renal Cell Carcinoma
NCT05522231 · Hutchmed
2022-10-27 – 2026-08-28 · Advanced Renal Cell Carcinoma
What this study did
Phase 2 (3)
Renal Cell Carcinoma
NCT06690697 · Fudan University
2024-06-01 – 2026-12-31 · Clear Cell Renal Cell Carcinoma
What this study did
NCT02639182 · Astellas Pharma Global Development, Inc.
2016-05-03 – 2020-10-02 · Metastatic Renal Cell Carcinoma
What this study did
Other / comorbidity
NCT03941795 · Peking University Cancer Hospital & Institute
2019-11-11 – 2022-12 · Advanced Mucosal Melanoma
What this study did
Appears in other studies (6)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (2)
Renal Cell Carcinoma
NCT07383441 · SWOG Cancer Research Network
2026-06-05 – 2034-01-31 · Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
What this study did
NCT06726421 · Sun Yat-sen University
2024-09-18 – 2033-09-30 · Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic
What this study did
Phase 2 (4)
Renal Cell Carcinoma
NCT05327686 · NRG Oncology
2023-02-01 – 2033-06-15 · Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
What this study did
NCT03092856 · University of Southern California
2017-07-19 – 2027-12-31 · Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
What this study did
NCT01727336 · Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
2012-12 – 2017-11 · Advanced Renal Cell Carcinoma
What this study did
NCT01441414 · Pfizer
2011-11-21 – 2014-03-27 · Metastatic Renal Cell Carcinoma
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Renal Cell Carcinoma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Axitinib: this drugApprovedSmall moleculeVEGFR1/2/3Partial signal
NCT02684006: Primaries in PD-L1-positive patients, avelumab + axitinib vs sunitinib: PFS (BICR) median 13.8 vs 7.2 months, hazard ratio 0.61 (95% CI 0.475 to 0.790), p=0.0001, met; OS median 43.2 vs 36.2 months, hazard ratio 0.86 (95% CI 0.701 to 1.057), p=0.1509, not significant (CT.gov posted results).
Aldesleukin (Proleukin)ApprovedRecombinant Cytokine (il-2)Interleukin-2 receptor (IL-2R)not yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AvelumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Belzutifan (Welireg)ApprovedSmall moleculeHIF-2alphanot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
CabozantinibApprovedSmall moleculeMET / VEGFR / AXL / RET (multi-kinase)Partial signalNo reviewed efficacy summary in this indication
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01668784: Overall Survival (OS) at Primary Endpoint (Randomization until 398 deaths, up to May 2015 (approximately 30 months)): Nivolumab 25 months | Everolimus 19.55 months (95% CI 17.64 to 23.06)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Pazopanib (Votrient)ApprovedSmall moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)Reliable signalFeatured results are non-efficacy only in this race
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02811861: Progression-free Survival (PFS) by Independent Imaging Review (IIR) (From the date of randomization to the date of the first documentation of PD or date of death, whichever occurred first or up to data cutoff date 28 Aug 2020 (up to approximately 46 months)): Lenvatinib 18 mg Plus Everolimus 5 mg 14.7 months (95% CI 11.1 to 16.7) | Lenvatinib 20 mg Plus Pembrolizumab 200 mg 23.9 months (95% CI 20.8 to 27.7) | Sunitinib 50 mg 9.2 months (95% CI 6 to 11)
NCT04704219: Objective Response Rate (ORR) (Up to approximately 47 months): Pembrolizumab + Lenvatinib 50.6 Percentage of participants (95% CI 42.6 to 58.7)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
DurvalumabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Fruquintinib (Fruzaqla / Elunate)Phase 3Small moleculeVEGFR1/2/3not yet gradedNo reviewed efficacy summary in this indication
Savolitinib (Orpathys)Phase 3Small moleculeMETnot yet gradedNo reviewed efficacy summary in this indication
ZanzalintinibPhase 3Small moleculeVEGFR2; MET; AXL; MER; TYRO3not yet gradedNo reviewed efficacy summary in this indication
CiforadenantPhase 1/2Small moleculeadenosine A2Anot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(25 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Axitinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
December 2026 (3)
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2026-12-30 · NCT05768464 · CT.gov ↗
What to watch
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2026-12-31 · NCT03297606 · CT.gov ↗
What to watch
Phase 3Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer, Solid TumorsActive not recruiting
Est. primary completion 2026-12-31 · NCT05059522 · CT.gov ↗
What to watch
2027 (14)
January 2027 (1)
Phase 2Pheochromocytoma, ParagangliomaActive not recruiting
Est. primary completion 2027-01 · NCT03839498 · CT.gov ↗
What to watch
February 2027 (2)
Phase 2Renal Cell CarcinomaNot yet recruiting
Est. primary completion 2027-02-20 · NCT07159191 · CT.gov ↗
What to watch
Phase 2Radiation Therapy, Targeted Therapy, Immunotherapy, Renal Cancer MetastaticRecruiting
Est. primary completion 2027-02-28 · NCT06889649 · CT.gov ↗
What to watch
May 2027 (2)
Phase 2Renal CancerRecruiting
Est. primary completion 2027-05 · NCT06962787 · CT.gov ↗
What to watch
Phase 2Mucosal MelanomaRecruiting
Est. primary completion 2027-05 · NCT05384496 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Cancer, Tumors, Neoplasm, NeoplasiaRecruiting
Est. primary completion 2027-09 · NCT02925234 · CT.gov ↗
What to watch
October 2027 (1)
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2027-10-01 · NCT07123090 · CT.gov ↗
What to watch
November 2027 (1)
Phase 1/2Renal Cell CarcinomaRecruiting
Est. primary completion 2027-11-02 · NCT07227415 · CT.gov ↗
What to watch
December 2027 (6)
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2027-12-30 · NCT07744932 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaNot yet recruiting
Est. primary completion 2027-12-30 · NCT07816770 · CT.gov ↗
What to watch
Phase 1Melanoma, Mucosal Melanoma, Metastatic MelanomaEnrolling by invitation
Est. primary completion 2027-12-31 · NCT06424626 · CT.gov ↗
What to watch
Phase 1Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid NeoplasmRecruiting
Est. primary completion 2027-12-31 · NCT04693468 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07776717 · CT.gov ↗
What to watch
Phase 3Renal Cell CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT05738694 · CT.gov ↗
What to watch
2028 (2)
March 2028 (1)
Phase 1/2Renal Cell CarcinomaNot yet recruiting
Est. primary completion 2028-03-01 · NCT07630363 · CT.gov ↗
What to watch
April 2028 (1)
Early phase / not applicableRenal Cell CarcinomaNot yet recruiting
Est. primary completion 2028-04 · NCT07500831 · CT.gov ↗
What to watch
2029 (4)
March 2029 (1)
Phase 1Renal Cell CarcinomaRecruiting
Est. primary completion 2029-03 · NCT05536141 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Cancer, Tumors, Neoplasms, NeoplasiaRecruiting
Est. primary completion 2029-04-30 · NCT04341181 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2029-10 · NCT07469683 · CT.gov ↗
What to watch
November 2029 (1)
Phase 2Renal Cell CarcinomaNot yet recruiting
Est. primary completion 2029-11-30 · NCT07277972 · CT.gov ↗
What to watch
2032 (2)
February 2032 (1)
Phase 1/2Medulloblastoma, EpendymomaRecruiting
Est. primary completion 2032-02 · NCT06485908 · CT.gov ↗
What to watch
May 2032 (1)
Phase 3Metastatic Kidney Cancer, Metastatic Kidney CarcinomaRecruiting
Est. primary completion 2032-05-05 · NCT06364631 · CT.gov ↗
What to watch

See the full readout calendar ↗